EUVIMEDEUVIMED entdecken
Validierungsstudie

Development and Validation of a Cell-Free DNA Fragmentomics–Based Model for Early Detection of Pancreatic Cancer

Lingdi Yin iD, Cheng Cao, Jianzhen Lin, Zheng Wang, Yunpeng Peng, Kai Zhang, Cheng Xu, Ruowei Yang, Dongqin Zhu, Fufeng Wang, Shuang Chang, Hua Bao iD und 21 weitere

Journal of Clinical Oncology · 10.09.2025 · 43 (26) · 2863-2874

DOI: 10.1200/jco.24.00287 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.09.2025. Verfasst von Lingdi Yin und 32 weiteren Autor:innen. Beteiligte Einrichtung: Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Early Detection of Cancer, Carcinoma, Pancreatic Ductal, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Pancreatic ductal adenocarcinoma (PDAC), known for its high fatality rate, is often diagnosed in its advanced stages where surgical options are not viable. This highlights the critical need for innovative and effective early detection techniques. This study focuses on the potential of cell-free DNA (cfDNA) fragmentomics integrating advanced machine learning to identify early-stage PDAC with high accuracy. METHODS Our study included a broad cohort of 1,167 participants, from which plasma was collected and subjected to shallow whole-genome sequencing. After rigorous quality assessments, 166 individuals diagnosed with PDAC and 167 healthy participants were in the training cohort, whereas the validation cohort consisted of 112 patients with PDAC and 111 healthy individuals. A separate group of 67 individuals with nonmalignant pancreatic cysts was also included to validate the model's accuracy. Finally, two additional external validation cohorts and one additional independent early-stage data set were included to evaluate the robustness of model. Our analysis used fragmentomic profiling, integrating copy-number variations, fragment size, mutational signatures, and methylation patterns analyzed using machine learning. RESULTS The model demonstrated remarkable accuracy in distinguishing patients with PDAC from controls, with an AUC of 0.992 in the training data set and 0.987 in the validation data set. At a cutoff of 0.52, the training set reached a sensitivity of 93.4% and a specificity of 95.2%. In the validation data set, the sensitivity was 97.3% with a specificity of 92.8%, while the external data set demonstrated a sensitivity of 90.91% and a specificity of 94.5%. CONCLUSION This study underscores the effectiveness of using cfDNA fragmentomics and machine learning for early detection of PDAC. Our approach promises significant potential in reducing PDAC mortalities through early intervention and could serve as a breakthrough in oncologic diagnostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsEarly Detection of CancerCarcinoma, Pancreatic DuctalCell-Free Nucleic AcidsBiomarkers, TumorHumansMaleFemaleMiddle AgedMachine LearningAgedCase-Control StudiesDNA Copy Number VariationsAdult

Substanzen

Cell-Free Nucleic AcidsBiomarkers, Tumor

Autor:innen und Institutionen

  • Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Pancreas Institute of Nanjing Medical University, Nanjing, China.
  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China.
  • Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Lingdi Yin, Hua Bao, Shanshan Yang, Ning Pu, Yi Miao, Zipeng Lu, Kuirong Jiang

Zitieren

APA

Yin, L., Cao, C., Lin, J., Wang, Z., Peng, Y., Zhang, K., Xu, C., Yang, R., Zhu, D., Wang, F., Chang, S., Bao, H., Yang, S., Li, N., Wu, X., Shao, Y., Wu, Z., Wu, S., Pu, N., …, & Jiang, K. (2025). Development and Validation of a Cell-Free DNA Fragmentomics–Based Model for Early Detection of Pancreatic Cancer. Journal of Clinical Oncology, 43(26), 2863-2874. https://doi.org/10.1200/jco.24.00287

Vancouver

Yin L, Cao C, Lin J, Wang Z, Peng Y, Zhang K, et al. Development and Validation of a Cell-Free DNA Fragmentomics–Based Model for Early Detection of Pancreatic Cancer. Journal of Clinical Oncology. 2025;43(26):2863-2874. doi:10.1200/jco.24.00287

BibTeX
@article{Yin2025,
  author = {Yin, Lingdi and Cao, Cheng and Lin, Jianzhen and Wang, Zheng and Peng, Yunpeng and Zhang, Kai and Xu, Cheng and Yang, Ruowei and Zhu, Dongqin and Wang, Fufeng and Chang, Shuang and Bao, Hua and Yang, Shanshan and Li, Ningyou and Wu, Xue and Shao, Yang and Wu, Zheng and Wu, Shuai and Pu, Ning and Xu, Zhihang and Guo, Feng and Feng, Xu and Chen, Jianmin and Xiao, Bin and Tu, Min and Li, Qiang and Wei, Jishu and Wu, Junli and Gao, Wentao and Miao, Yi and Liu, Liang and Lu, Zipeng and Jiang, Kuirong},
  title = {Development and Validation of a Cell-Free DNA Fragmentomics–Based Model for Early Detection of Pancreatic Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {26},
  pages = {2863--2874},
  doi = {10.1200/jco.24.00287}
}
Kostenlos starten →